Skip to main
IDYA

IDYA Stock Forecast & Price Target

IDYA Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 57%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

IDEAYA Biosciences is an up and coming company with a promising pipeline of clinical-stage product candidates. Its recently announced positive data on its lead asset, darovasertib, for metastatic uveal melanoma has de-risked potential future readouts and increased the potential market size for the drug. Additionally, the company's synthetic lethality platform has shown early clinical success and provides additional opportunities for revenue. However, as with any other biotechnology company, there are risks associated with R&D, regulatory setbacks, and competition, which could impact the company's future success.

Bears say

IDEAYA Biosciences is an oncology-focused precision medicine company that has six clinical-stage product candidates and multiple preclinical programs in development. However, its safety and tolerability profile for its main drug combination, darovasertib and crizo, has been underwhelming with most common Grade 3+ adverse events including diarrhea and syncope. Additionally, their valuation for 2030, based on discounted sales projections, is high and dependent on the success of their pipeline programs, which have yet to be clearly defined.

IDYA has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 57% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ideaya Biosciences Inc (IDYA) Forecast

Analysts have given IDYA a Buy based on their latest research and market trends.

According to 14 analysts, IDYA has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ideaya Biosciences Inc (IDYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.